Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430183 · ClinicalTrials.gov registry record · Phase 3
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 788
- Enrollment target
- 20
- Study locations
NCT00430183 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 788 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (30% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00430183, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 788 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin and leuprolide, may stop the adrenal glands from making androgens. Giving docetaxel and leuprolide or goserelin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether giving docetaxel and leuprolide or goserelin before surgery is more effective than surgery alone in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying docetaxel and leuprolide or goserelin to see how well they work when given before surgery compared with surgery alone in treating patients with high-risk localized prostate cancer.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG LHRH agonist
- PROCEDURE surgery
Study Locations (20)
California
- Alta Bates Summit Comprehensive Cancer Center - Berkeley
- Peninsula Medical Center - Burlingame
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Sutter Health - Western Division Cancer Research Group - Novato
- University of California Davis Cancer Center - Sacramento
- Naval Medical Center - San Diego - San Diego
- California Pacific Medical Center - Pacific Campus - San Francisco
- Sutter Pacific Medical Foundation - Santa Rosa
- Tahoe Forest Cancer Center - Truckee
- Sutter Solano Medical Center - Vallejo
Colorado
- University of Colorado Cancer Center at UC Health Sciences Center - Aurora
- Denver Health Medical Center - Denver
- Veterans Affairs Medical Center - Denver - Denver
- Shaw Regional Cancer Center - Edwards
- Valley View Hospital Cancer Center - Glenwood Springs
- Montrose Memorial Hospital Cancer Center - Montrose
Alaska
- Providence Cancer Center - Anchorage
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital - Fairbanks
Connecticut
- Helen and Harry Gray Cancer Center at Hartford Hospital - Hartford
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 788 participants |
| Start Date | 2007-05-08 |
| Est. Completion | 2030-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430183
The ClinicalTrials.gov registry entry for NCT00430183 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 788 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (30% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which docetaxel is the first listed.
NCT00430183 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Alaska.
Frequently Asked Questions
What is clinical trial NCT00430183 about?
NCT00430183 is a clinical study titled "Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer". RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin and leuprolide, may stop ...
What is the current status of trial NCT00430183?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 788 participants. The study started on 2007-05-08. Estimated completion is 2030-10.
What conditions does trial NCT00430183 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00430183?
The interventions under investigation include: docetaxel (DRUG), LHRH agonist (DRUG), surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00430183?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00430183 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.